Source: Media Outreach
IRVINE, CA. – News Aktuell – 12 April 2021 – Fluxergy, Inc., a medical diagnostic testing platform company with a detection technology solution capable of multimodality, announced today that it has obtained CE marking for its one-hour COVID-19 RT-PCR test, to use by healthcare professionals as an in vitro diagnostic (IVD) for the detection of SARS-CoV-2. The CE-mark will allow Fluxergy’s innovative testing platform to enter the European Union market and any other markets that accept CE-marking as valid regulatory approval.
The Fluxergy Diagnostic System: The Fluxergy Analyzer, which conducts the testing; the Fluxergy Card, a single-use test cartridge and its reagents; and the FluxergyWorks software, to manage the test data. The Fluxergy Test Kit COVID-19 is only available for purchase in the European Union market and any other markets that accept the CE-marking as valid regulatory approval. COURTESY: FLUXERGY, INC.
Fluxergy, Inc Receives CE-IVD Marking for a One-Hour COVID-19 RT-PCR Test and Positions for European Market Entry realwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from realwire.com Daily Mail and Mail on Sunday newspapers.
April 8, 2021
Philips and Ibex Medical Analytics cooperate to globally commercialize clinically proven, AI-powered digital pathology solutions
Combination of Philips’ digital pathology solutions and Ibex’s AI-powered Galen platform has improved reporting efficiency by 27%, driven 37% productivity gains, and improved consistency and accuracy to enhance diagnostic confidence
Collaboration furthers Philips’ commitment to integrated diagnostics providing a clear path to precision diagnosis
Amsterdam, The Netherlands and Tel Aviv, Israel –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
Ibex Medical Analytics, a pioneer in artificial intelligence (AI) based cancer diagnostics, today announced a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide. The combination of Philips digital pathology solution (
Philips and Ibex Medical Analytics team to accelerate adoption of AI-powered digital pathology
April 8, 2021
Philips and Ibex Medical Analytics cooperate to globally commercialize clinically proven, AI-powered digital pathology solutions
Combination of Philips’ digital pathology solutions and Ibex’s AI-powered Galen platform has improved reporting efficiency by 27%, driven 37% productivity gains, and improved consistency and accuracy to enhance diagnostic confidence
Collaboration furthers Philips’ commitment to integrated diagnostics providing a clear path to precision diagnosis
Amsterdam, The Netherlands and Tel Aviv, Israel –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
Ibex Medical Analytics, a pioneer in artificial intelligence (AI) based cancer diagnostics, today announced a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide. The combi